Tag Archives: type-industry &amp; policy

No account yet? Register

Bio-Techne and ZERO – The End of Prostate Cancer Announce Partnership to Fund Education and Awareness Campaigns to Empower Men with Prostate Cancer

Bio-Techne Corporation announced that Exosome Diagnostics has established a new partnership with ZERO – The End of Prostate Cancer.

[Bio-Techne Corporation]

No account yet? Register

Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase I/II Trial

Principia Biopharma, Inc. announced positive data on durability of response from an ongoing Phase I/II trial of its investigational treatment, rilzabrutinib.

[Principia Biopharma, Inc.]

No account yet? Register

US Science Groups Wary of New Senate Bills to Curb Foreign Influences

A bipartisan group of US senators proposed sweeping—and controversial—changes in how the federal government manages academic research in the face of threats from other countries.

[ScienceInsider]

No account yet? Register

Emmes Announces Its Work on a Phase III Clinical Trial for Breakthrough Therapy Designation Product

Emmes announced that it provided the Phase III clinical trial support for a new investigational cell therapy that offers a promising treatment opportunity for patients who need an allogeneic bone marrow transplant.

[Emmes (PR Newswire, Inc.)]

No account yet? Register

Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device

Nuvaira announced that its Nuvaira^® Lung Denervation System has been designated as a Breakthrough Device by the FDA.

[Nuvaira]

No account yet? Register

Creatv Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer Using a Simple Blood Test

Creatv Microtech has pioneered a blood test to predict treatment response in patients with stage II-III NSCLC treated with chemoradiation therapy and consolidated immunotherapy.

[Business Wire, Inc.]

No account yet? Register

Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology

Lassen Therapeutics announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and oncology.

[Lassen Therapeutics]

No account yet? Register

Bellicum Receives FDA IND Clearance to Initiate a Phase I/II Clinical Trial for BPX-603, a Dual-Switch GoCAR-T^® for HER2+ Solid Tumors

Bellicum Pharmaceuticals, Inc. announced clearance by the FDA of its investigational new drug application for BPX-603. BPX-603 is a GoCAR-T^® product candidate targeting solid tumors that express human epidermal growth factor receptor 2 (HER2).

[Bellicum Pharmaceuticals, Inc.]

No account yet? Register

Immune Status Could Determine Efficacy of COVID-19 Therapies

Emerging evidence suggests that SARS-CoV-2 can drive a diverse array of immune processes, raising the risk that immunosuppressant agents that are in clinical trials might be effective for some patients but detrimental for others.

[Nature Reviews Drug Discovery]

No account yet? Register

How Deadly Is the Coronavirus? Scientists Are Close to an Answer

Researchers use a metric called infection fatality rate (IFR) to calculate how deadly a new disease is. It is the proportion of infected people who will die as a result, including those who don’t get tested or show symptoms.

[Nature News]